Marker vaccine for classical swine fever

US9315873B2 · kind B2 · utility

Assignee

• IDT Biologika GmbH · DE

Inventors

• Martin Beer · Greifswald, DE
• Sandra Blome · Grimmen, DE
• Immanuel Leifer · Groß Kiesow, DE

Key dates

• Filing date: May 18, 2011
• Grant date: Apr 19, 2016
• Expiry date: Nov 25, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/24334
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a marker vaccine for prophylactic treatment of classical swine fever comprising modified live attenuated classical swine fever virus. The viral amino acid sequence of the TAV-epitope of the E2 protein comprises a different sequence from that of a wild-type classical swine fever virus. The invention relates to pharmaceutical compositions of the marker vaccine. The invention also relates to a method of manufacturing marker vaccines for prevention of classical swine fever using selective antibody pressure.